Philips buys BioTelemetry for US$2.8b
[AMSTERDAM] Royal Philips agreed to buy US-based BioTelemetry for US$2.8 billion to expand in wearable heart monitors as the Dutch company expands in the burgeoning at-home care market.
Shareholders of Conshohocken, Pennsylvania-based BioTelemetry will receive US$72 a share in cash, Philips said in a statement Friday, a 17 per cent premium over Thursday's closing price.
With the global coronavirus pandemic still raging, demand for Philips' equipment that allows doctors and nurses to provide real-time care over the cloud is surging. The Amsterdam-based company expects the BioTelemetry purchase to add to sales growth and expand its profit margin in 2021.
The bulk of BioTelemetry's sales come from equipment to diagnose and monitor heart disorders, with AI-based data analytics used to pick up abnormalities. It's a market worth more than US$3 billion and growing, Philips said in its statement.
BLOOMBERG
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue